Amicus Therapeutics, Inc. (FOLD) Sees Large Drop in Short Interest

Amicus Therapeutics, Inc. (NASDAQ:FOLD) saw a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 27,464,314 shares, a decrease of 7.6% from the January 12th total of 29,723,183 shares. Based on an average daily trading volume, of 3,192,320 shares, the days-to-cover ratio is presently 8.6 days. Currently, 17.0% of the company’s shares are short sold.

In other Amicus Therapeutics news, COO Bradley L. Campbell sold 32,500 shares of the stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $15.92, for a total transaction of $517,400.00. Following the completion of the sale, the chief operating officer now owns 186,600 shares of the company’s stock, valued at approximately $2,970,672. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Daphne Quimi sold 8,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $14.72, for a total transaction of $117,760.00. Following the sale, the senior vice president now directly owns 62,676 shares of the company’s stock, valued at approximately $922,590.72. The disclosure for this sale can be found here. Insiders sold 250,390 shares of company stock valued at $3,620,581 in the last ninety days. 3.40% of the stock is currently owned by insiders.

Several hedge funds have recently made changes to their positions in FOLD. Eagle Asset Management Inc. acquired a new stake in shares of Amicus Therapeutics during the 3rd quarter worth approximately $40,450,000. Jennison Associates LLC grew its position in shares of Amicus Therapeutics by 9.4% during the 3rd quarter. Jennison Associates LLC now owns 9,772,025 shares of the biopharmaceutical company’s stock worth $147,362,000 after buying an additional 838,267 shares during the period. Allianz Asset Management GmbH acquired a new stake in shares of Amicus Therapeutics during the 3rd quarter worth approximately $11,381,000. Perceptive Advisors LLC grew its position in shares of Amicus Therapeutics by 3.4% during the 3rd quarter. Perceptive Advisors LLC now owns 17,888,597 shares of the biopharmaceutical company’s stock worth $269,760,000 after buying an additional 591,925 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Amicus Therapeutics by 5.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock worth $91,821,000 after buying an additional 430,486 shares during the period.

A number of research firms have weighed in on FOLD. ValuEngine raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Robert W. Baird set a $20.00 target price on shares of Amicus Therapeutics and gave the company a “buy” rating in a research report on Wednesday. Leerink Swann increased their target price on shares of Amicus Therapeutics from $20.00 to $24.00 and gave the company an “outperform” rating in a research report on Thursday. Zacks Investment Research raised shares of Amicus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, January 17th. Finally, BidaskClub raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $19.06.

Shares of Amicus Therapeutics (NASDAQ:FOLD) opened at $14.72 on Friday. The company has a market cap of $2,450.00, a P/E ratio of -8.04 and a beta of 1.45. Amicus Therapeutics has a 52-week low of $5.87 and a 52-week high of $17.40. The company has a current ratio of 6.32, a quick ratio of 6.22 and a debt-to-equity ratio of 0.39.

COPYRIGHT VIOLATION WARNING: This article was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/02/10/amicus-therapeutics-inc-fold-sees-large-drop-in-short-interest.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply